Serological, clinical and epidemiological aspects of Lyme borreliosis in Mures County, Romania

Open access

Abstract

Lyme borreliosis (LB) is the most frequent infection transmitted by ticks from the Ixodes genus, both in the United States of America (USA), and in Europe. The objectives of this study were the monitoring of the incidence and clinical manifestations of the disease in Mures County, Romania. Material and method. The study was conducted over a period of two years, January 1st 2010 -December 31st 2011, on a number of 120 consecutive patients. The definite or probable diagnosis of LB was established on the Centers for Disease Control and Prevention (CDC, Atlanta, USA) criteria, and on the European Union Concerted Action on Lyme borreliosis (EUCALB). ELISA and Western-Blot techniques were used for identification of IgM and IgG antiBb from the serum and CSF. Results. There were 44 cases in 2010 and 76 cases in 2011. According to the case definition, 106 cases were confirmed as LB and 14 were probable. LB was more frequently diagnosed in children, young adults and adults, compared to the over 60 years old age group. The incidence of disease was higher in women patients, 68 (56.66%) compared to men - 52 patients (43.33%), with a higher proportion in people coming from an urban setting, 78 patients (65%), compared to people coming from rural settings 42 patients (35%). Clinical manifestations were acute, like erythema migrans (EM) in 64.16% of the patients, neurological in 22.5% of the patients, joint related in 1.66% of the patients and cardiac in 0.83% of the cases. Conclusions. In Mures County we have observed an increased incidence of this disease in 2011 vs. 2010. The predominant clinical manifestations were the acute dermatological and neurological ones.

1. Stanek G, Fingerle V, Hunfeld KP, Jaulhac B, Kaiser R, Krause A, et al. Lyme borreliosis: clinical case definition for diagnosis and management in Europe. Clin Microbiol Infect. 2011 Jan;17(1):69-79 DOI: 10.1111/j.1469-0691.2010.03175.x

2. Wright WF, Riedel DJ, Talwani R, Gilliam BL. Diagnosis and Management of Lyme disease. Am Fam Physician. 2012 Jun 1; 85(11):1086-93

3. Wormser GP, Brisson D, Liveris D, Hanincora K, Sandigursky S, et al. Borrelia burgdorferi genotype predicts the capacity for hematogenous dissemination during early Lyme disease. J Infect Dis. 2008 Nov 1;198(9):1358-64 DOI: 10.1086/592279

4. Wormser GP, Dattwyler RJ, Shapirro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006 Nov 1;43(9):1089-134 DOI: 10.1086/508667

5. Coipan EC, Vladimirescu AF: Ixodes ricinus ticks (Acari: Ixodidae): vectors for Lyme disease spirochetes in Romania. Exp Appl Acarol. 2011 Jul;54(3):293-300 DOI: 10.1007/s10493-011-9438-4

6. Lindgren E, Jaenson TGT: Lyme borreliosis in Europe. Influences of climate and climate change, epidemiology, ecology and adaptation measures, World Health Organization, Regional Office for Europe, Copenhagen, Denmark. 2006;5-24 [http://www.euro.who.int/__data/ assets/pdf_file/0006/96819/E89522.pdf]

7. European Concerted Action on Lyme Borreliosis. Diagnosis: Case Definition EUCALB: [http://eucalb.com/]

8. Wilske B, Fingerle V, Schulte-Spechtel U. Microbiological and serological diagnosis of Lyme borreliosis. FEMS Immunol Med Microbiol. 2007;49(1):13-21. Review DOI: 10.1111/j.1574-695X.2006.00139.x

9. Centrul Național de Supraveghere şi Control al Bolilor Transmisibile - Boala Lyme - metodologie de supraveghere: Lyme borreliosis. [http://www.insp.gov. ro/cnscbt/index.php?option=com_docman&task=cat_ view&gid=34&Itemid=10] [in Romanian]

10. Centers for Disease Control and Prevention United States: Effect of electronic laboratory reporting on the burden of Lyme disease surveillance: New Jersey, 2001-2006. MMWR. 2008 Jan;57(2):42-5

11. Hristea A, Hristescu S, Ciufecu C, Vasile A: Seroprevalence of Borrelia burgorferi in Romania. Eur J Epidemiol. 2001;17(9):891-6 DOI: 10.1023/A:1015600729900

12. Semenza JC, Suk JE, Estevez V, Ebi KL, Lindgren E. Mapping Climate Change Vulnerabilities to Infectious Disease in Europe. Environ Health Perspect. 2012 Mar;120(3):385-92 DOI: 10.1289/ehp.1103805

13. Stanek G, Strle F. Lyme borreliosis: a European perspective ondiagnosis and clinical management. Curr Opin Infect Dis. 2009 Oct;22(5):450-4 DOI: 10.1097/ QCO.0b013e32832ee880

14. Rizzoli A, Hauffe HC, Carpi G, Vourch GI, Neseler M, Rosa R. Lyme borreliosis in Europe. Eurosurveillance. 2011 Jul;16(27):1-6

15. Halperin JJ, Shapiro ED, Logigian EL, Belman AL, Dotevall L, et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2007 Jul;69(1):91-102 DOI: 10.1212/01. wnl.0000265517.66976.28

16. Țilea B, Chiriac C, Țilea I, Urcan R, Tripon G, Gliga M. Diagnostic, therapeutic and evolutive particularities of Lyme disease. Rev Romana Med Lab. 2009 Jun;15(2):55-60

17. O’Connel S. Lyme borreliosis: current issues in diagnosis and management. Curr Opin Infect Dis. 2010 Jun;23(3):231-5 DOI: 10.1097/ QCO.0b013e32833890e2

18. Ljostad U, Skogvoll E, Eikeland R, Skarpaas T, et al. Oral doxycycline versus intravenous ceftriaxon for European Lyme neuroborreliosis: a multricentric, non-inferiority, double blind, randomised trial. Lancet Neurol. 2008 Aug;7(8):690-5 DOI: 10.1016/S1474-4422(08)70119-4

19. Smith R, Takkinnen J. Lyme borreliosis: Europe-wide coordinated surveillance and action nedeed? Euro Surveill. 2006 Jun;11(6):E060622.1

20. Skogman BH, Glimåker K, Nordwall M, Vrethem M, Ödkvist L, Forsberg P. Long-term clinical outcome after Lyme neuroborreliosis in childhood. Pediatrics. 2012 Aug;130(2):262-9 DOI: 10.1542/peds.2011-3719

21. Albrecht P, Henke N, Lehmann HC, Macht S, Hefter H et al. A case of relapsing -remitting neuroborreliosis? Challenges in the differential diagnosis of recurrent myelitis. Case Rep Neurol. 2012 Jan;4(1):47-53 DOI: 10.1159/000337223

22. Fallon BA, Levin ES, Schweitzer PJ, Hardesty D. Inflammation and central nervous system Lyme disease. Neurobiol Dis. 2010 Mar;37(3):534-41. DOI: 10.1016/j.nbd.2009.11.016

23. Wormser GP, Nadelman RB, Schwartz I.The amber theory of Lyme arthritis: initial description and clinical implications. Clin Reumatol. 2012 Jun;31(6):989-94 DOI: 10.1007/s10067-012-1964-x

24. Puius YA, Kalish RA. Lyme arthritis: pathogenesis, clinical presentation, and management. Infect Dis North Am. 2008 Jun;22(2):289-300 DOI: 10.1016/j. idc.2007.12.014

25. Costello JM, Alexander ME, Greco KM, Perez AR, Laussen PC. Lyme carditis in children: presentation, predictive factors, and clinical course. Pediatrics. 2009 May;123(5):835-41 DOI: 10.1542/peds.2008-3058

26. Lo R, Meuzies DJ, Archer H, Cohen TJ.J.Complete heart block due to Lyme carditis: Invasive Cardiol. 2003 Jun;15(6):367-9

27. Koene R, Boulware DR, Kemperman M, Konety SH, Groth M, et al. Acute hearth failure from lyme carditis. Circ Heart Fail. 2012 Mar;5(2):e24-6 DOI: 10.1161/ CIRCHEARTFAILURE.111.965533

Revista Romana de Medicina de Laborator

Romanian Journal of Laboratory Medicine

Journal Information


IMPACT FACTOR 2017: 0.400
5-year IMPACT FACTOR: 0.320



CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2017: 0.144
Source Normalized Impact per Paper (SNIP) 2017: 0.195

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 95 95 17
PDF Downloads 33 33 4